Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 27 of the 41 sources its claims cite were checked for support.
Abstract
BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis. RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group. CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).
Overview
CoChat Summary
TL;DR
In a phase 3 trial of patients with genetically identified familial chylomicronemia syndrome, olezarsen 80 mg every 4 weeks significantly reduced fasting triglycerides at 6 months versus placebo, while the 50-mg dose did not. Olezarsen also reduced apolipoprotein C-III and was associated with fewer adjudicated acute pancreatitis episodes over 53 weeks.
Key findings
- The 80-mg olezarsen group had a least-squares mean reduction in fasting triglycerides from baseline to 6 months of −43.5 percentage points versus placebo (95% CI, −69.1 to −17.9; P<0.001); the 50-mg dose did not meet significance (−22.4 percentage points; 95% CI, −47.2 to 2.5; P=0.08).
- Apolipoprotein C-III reductions from baseline to 6 months were −73.7 percentage points for 80 mg vs placebo (95% CI, −94.6 to −52.8) and −65.5 percentage points for 50 mg vs placebo (95% CI, −82.6 to −48.3).
- By 53 weeks, adjudicated acute pancreatitis occurred in 11 episodes in the placebo group and 1 episode in each olezarsen group (rate ratio for pooled olezarsen vs placebo, 0.12; 95% CI, 0.02 to 0.66).
- Adverse events of moderate severity considered related to trial drug or placebo occurred in 4 patients (18%) in the 80-mg olezarsen group.
Methods
- Phase 3, double-blind, placebo-controlled trial conducted from November 2020 through October 2023 at 29 centers in 11 countries; 66 patients with genetically identified familial chylomicronemia syndrome were randomized to olezarsen 80 mg (n=22), olezarsen 50 mg (n=21), or placebo (n=23) subcutaneously every 4 weeks for 49 weeks.
- Patients had fasting triglycerides ≥880 mg/dL and biallelic loss-of-function variants in LPL or related genes; baseline mean triglyceride level was 2630±1315 mg/dL, and 71% had a history of acute pancreatitis within the previous 10 years.
- Primary endpoints were hierarchical: difference between 80 mg and placebo in percent change in fasting triglycerides from baseline to 6 months, then the same for 50 mg vs placebo; secondary endpoints included apolipoprotein C-III change and independently adjudicated acute pancreatitis.
Limitations
- The paper states the trial cohort was small and there was uncertainty about adherence to dietary restrictions, which could have affected triglyceride lowering and acute pancreatitis incidence.
- The paper states the trial included mostly White patients, partly owing to genetic founder effects in European populations, and that larger, more diverse trials are needed.
- The paper notes that because the second primary endpoint was not significant, secondary endpoint results cannot be interpreted as definitive hypothesis tests and their confidence intervals were not adjusted for multiplicity; it also states postprandial fluctuations were not measured.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 3 Not valid · 7 Not checked · 64 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Olezarsen is an investigational GalNAc 3 -conjugated antisense oligonucleotide that reduces apolipoprotein C-III production by binding to APOC3 mRNA and inducing its degradation through ribonuclease H1-mediated cleavage of the sense strand. 26,28,29”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Partly supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) sourceExperimental — accuracy not yet measured
The Introduction describes AKCEA-APOCIII-LRx as a GalNAc3-modified antisense oligonucleotide targeting hepatic APOC3 mRNA, and the Discussion reports reduced plasma apoC-III. Our copy does not identify it by the name olezarsen or describe ribonuclease H1-mediated cleavage of the sense strand; those details are not supported by this source. (LLM, conf=0.86)
- Partly supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. sourceExperimental — accuracy not yet measured
The Introduction (p. 4) identifies olezarsen as a GalNAc-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apoC-III production. Our copy does not specify that its conjugate is GalNAc3 or describe mRNA degradation through ribonuclease H1-mediated cleavage of the sense strand. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The condition is caused by biallelic loss-of-function variants in LPL (encoding lipoprotein lipase) or in related genes needed for LPL activity. 10-12”
What the sources say
- Supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. source
The Introduction (p. 2) identifies homozygous or compound-heterozygous loss-of-function mutations in LPL and genes involved in LPL function as causes of FCS. Disease classification (p. 3) also lists homozygous loss-of-function mutations in related genes and compound-heterozygous mutations. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.1 describes FCS as an autosomal recessive monogenic disease caused by mutations in genes encoding key molecules of the lipolytic cascade. Sections 1.2 and 3 identify LPL and four genes needed for its activity as causes when mutated and dysfunctional. The paper does not use the exact phrase “biallelic loss-of-function,” but its description supports that paraphrase. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Loss of LPL activity results in a reduced ability to hydrolyze triglycerides in triglyceride-rich lipoproteins, such as intestinally derived chylomicrons and hepatically derived very-low-density lipoproteins, leading to their accumulation in plasma and subsequent severe hypertriglyceridemia. 10-12”
What the sources say
- Partly supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. sourceExperimental — accuracy not yet measured
The Introduction (p. 2) says LPL hydrolyses triglycerides and that loss of LPL function impairs clearance of intestinally derived chylomicrons. Disease classification (p. 3) links LPL deficiency in FCS with severe, persistent hypertriglyceridemia. Our copy does not establish the citing sentence’s additional point about hepatically derived VLDL accumulating through this mechanism. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.2 states that LPL hydrolyzes triglycerides in chylomicrons and VLDL. Section 3 links impaired lipolysis of triglyceride-rich lipoproteins to chylomicronemia, and Section 2 reports severe hypertriglyceridemia in patients with LPL deficiency. Together, these passages support the attributed causal chain. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and these agents have not been effective in lowering triglyceride levels in patients with familial chylomicronemia syndrome. 21,34”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J 2022; 43: 1413-5. source
- Could not verifycites [34] 34. Borén J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 2020; 11: 474. sourceExperimental — accuracy not yet measured
The Pharmacological Interventions section says fibrates have variable effects on APOC3 expression and omega-3 fatty acids moderately reduce apoC-III levels. It reports triglyceride lowering in familial chylomicronemia syndrome with volanesorsen, but does not address whether fibrates or omega-3 fatty acids fail to lower triglycerides in those patients (searched for familial chylomicronemia and conventional treatments). (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) source
The Discussion reports that AKCEA-APOCIII-LRx targets APOC3 mRNA and significantly lowers plasma apoC-III and triglycerides in subjects with hypertriglyceridaemia. The paper describes the drug as hepatocyte-targeted and as inhibiting apoC-III protein synthesis. It uses the developmental name AKCEA-APOCIII-LRx rather than olezarsen. (LLM, conf=0.87)
- Supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. source
The Introduction (p. 4) states that olezarsen targets hepatic APOC3 mRNA to inhibit apoC-III protein production. The Methods and results (p. 2) report significant reductions in fasting triglyceride levels with olezarsen compared with placebo. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
36 more claims · 4 with their cited sources checked
Create a free account to see all 89 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 33
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LDL Cholesterol(LDL-C) increased significantly in the olezarsen group at 6 months (MD = 52.75%;95% CI: 42.17, 63.33; P=.00001;I 2 = 31%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“and at 12 months (MD = -22.90%;95% CI: -26.47, -19.32;P=.0001;I 2 = 0%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Subgroup analyses evaluating dose-dependent effects showed significant reductions in TG levels at both the 50-mg dose (MD = -50.81;95% CI: -63.28, -38.34;P = .0001;I² = 64%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citation
Research works printed but not linked: 1
- 11. United States adults. Am J Cardiol 2011; 107: 891-7.
Cited by
Items 201–267 of 267
Joshy, J., Javed, A., Singh, M. K., Singh, B., Kumar, R., & Hussain, S. (2025) · Cureus · doi:10.7759/cureus.96715 · Cited by 5
“Notably, by 12 months, only one acute pancreatitis event occurred in each of the olezarsen arms (80 mg and 50 mg) versus 11 events in the placebo group, highlighting a dramatic reduction in this life-threatening complication [11].”
InfluentialOlezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial
Gouni‐Berthold, I. (2025) · Med · doi:10.1016/j.medj.2025.100923
Familial chylomicronemia in children: clinical cases
Sadykova, D. I., Рашидовна, С. Д., Шакирова, А. Р., Sayfullina, R. M., Damotsev, I. V., Bulatova, А. K., Gagieva, Z. A., Хабибрахманова, З. Р., & Сластникова, Е. С. (2025) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2025-70-5-91-96
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Yao, L., Yang, X., Sutton, R., Xia, Q., & Huang, W. (2025) · MedComm · doi:10.1002/mco2.70554
Feroz, K., Parvez, A., Ramzan, N. U. H., Asghar, T., Cheema, A. H., Malik, A. P., Fatima, T., Iqbal, J., & Sathian, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/9984822
“Two studies also included participants with a history of acute pancreatitis, a recognized adverse e ff ect of high triglyceride levels [7, 15].”
InfluentialFujioka, Y., Tanaka, S.-I., Tsujino, T., Ishida, T., & Hirata, K. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66073
Wie lässt sich das Pankreatitisrisiko senken?
Klose, G. (2026) · Gastro-News · doi:10.1007/s15036-025-3968-9
The hidden burden of kidney damage in chylomicronemia syndromes
D’Erasmo, L., Tramontano, D., Costanzo, A. D., Bini, S., Pasquali, M., Commodari, D., Arizaj, I., Pecce, V., Cerbelli, B., Minicocci, I., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120621
Self-citationBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Le syndrome d’hyperchylomicronémie familiale (SHF)
Langlois, C., & Charrière, S. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.01.003
Khan, M., Alhammad, A. A., Almalty, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8766708/v1
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
“In patients with familial chylomicronemia syndrome, both olezarsen and plo-zasiran reduce risk of pancreatitis, but these studies are not able to evaluate effects on the risk of ASCVD [10,11].”
La, N., Rattanapitoon, S. K., Thanchonnang, C., & Rattanapitoon, N. K. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.012
Vergès, B. L. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48948-8
Tsouka, A. N., Pechlivani, L., Koutsaliaris, I. K., & Tselepis, A. D. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_10_25
Ahmad, C. M., Kastle, R.-A., Patel, H., Haberman, S. R., & Youkhana, M. (2026) · Cureus · doi:10.7759/cureus.105594
Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.052
Horwacik, J., Maligłówka, M., Bułdak, Ł., & Okopień, B. (2026) · Livers · doi:10.3390/livers6020025
“Overall, adverse events occurred more frequently in the placebo group than in any of the olezarsen groups [112].”
Symptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life
Aboheimed, G. I., AlRasheed, M. M., AlFattani, A. A. G., Alhusayn, K. O., Alali, S., khbiah, R. A. A., Çolak, D., Al-Ashwal, A. A., & Kaya, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.021
施东雯, Luo, Y., Zhang, P., Liang, B., Wang, M., Cai, H., & Pang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744789
“Thus, APOC3 upregulation provides an upstream, shared molecular pathological basis for metabolic co-morbidity modules such as “ fatty liver-type 2 diabetes-hyperlipidemia ” within the Ising network (24).”
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
“The 12-month observed placebo-adjusted change in the 80 mg group was reported to be −59% points, illustrating sustained efficacy [60].”
Self-citationEmara, A., Awashra, A., Aboeldahab, H. A., Gadelmawla, A. F., Abdul‐Hafez, H. A., Alharran, A. M., Alsubaiei, A. A., AlRumaihi, M. J., Albuhmaid, S. A., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70220
Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. Authors' Reply
Loomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70692
Kessler, A. S., Vera‐Llonch, M., Alexander, V. J., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.019
Self-citationЕпидемиология на фамилен хиломикронемичен синдром
Стефанов, Г., & Георгиева, М. (2026) · Редки болести и лекарства сираци · doi:10.36865/2026.v17i1.240
Atherogenic apolipoprotein C-III may not be as bad as we thought
Smith, A. N., Zhang, Z., & Zheng, Z. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.02.023
Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies
Chamerski, S., Wartecka-Zielińska, K., Pomorski, F., Karos, W., Marlęga-Linert, J., Marcinkowska, M., Stefańska, K., Grzybowska, M. E., Wydra, D. G., Gruchała, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1761761 · Cited by 2
“Four moderate adverse events were reported among patients receiving the higher dose of olezarsen (76).”
Kessler, A. S., Serafini, P., Pushkarna, D., Pourrahmat, M., Baum, S. J., Tsimikas, S., & Vera-Llonch, M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.001
Self-citationTargeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Khalil, I., Hossain, M. I., Khalid, A. A., & Sarker, P. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10019-3
“Their work pools data from three pivotal RCTs: the BALANCE trial [5] and the two CORE-TIMI 72 trials (CORE-TIMI 72a and CORE-TIMI 72b) [6], totaling 1,127 adults followed for up to 12 months.”
Kessler, A. S., Brown, T. M., Basnyat, B., Yarlas, A. S., & Dine, J. L. (2026) · Patient Related Outcome Measures · doi:10.1080/1179271x.2026.2672471
Li, Y., Wang, Y., Wan, X., & Huang, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8998566/v1
Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies
Vermeer, C., Venema, R. R., Birnie, E., Bolling, M. C., Knoers, N. V. A. M., Bremer, J., & van den Akker, P. C. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102976 · Cited by 1
Hafthar, R. R., Alibare, R. A., Afeez, M. A., & Aziz, A. (2026) · Cureus · doi:10.7759/cureus.110536
Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis
Khan, N., Shahid, H., Choudhry, H. H. A., Irshad, M., Shaikh, H. A., Shahid, S., Afridi, F. N., Mian, S. M., Mateen, L., Khan, H., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001341
Hegele, R. A. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001048 · Cited by 2
Self-citationSoran, H., Kessler, A. S., Vera-Llonch, M., Alexander, V. J., Serafini, P., Pushkarna, D., Rodrigues, E., Stroes, E. S. G., Schatz, U., Kassner, U., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0069 · Cited by 1
“The placebo-anchored MAIC [17] was conducted using IPD from the Balance [15] study and aggregate-level data from the APPROACH [19] trial.”
InfluentialSelf-citationKassem, B. A., Shaik, F. A., Sorour, O., Abdelhamid, A. H., Fazal, A., Dakroub, A. H., & Eid, A. H. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001846
Wang, L., He, M., Xie, H., Mao, W., Liu, Y., Ke, L., 邹鑫森, & Li, W. (2026) · European journal of medical research · doi:10.1186/s40001-026-04732-y
Li, Y., Zhou, X., Wen, Y., Huang, Q., Yang, X., Mukherjee, R., Sutton, R., Liu, T., Cai, W., & Huang, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071574 · Cited by 3
“From a pathophysiological perspective, FCS represents a “pure” model of TG-driven AP [36], providing key insights into the direct lipotoxic effects of chylomicron-derived free fatty acids (FFAs) and their role in acinar cell injury and microvascular dysfunction.”
Labenz, J., & Madisch, A. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2869-1150
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Jaffe, G. J., Wykoff, C. C., McCaleb, M. L., Barrett, T. D., Frazer-Abel, A., Norris, D., Luhmann, U. F. O., Cukras, C., Yin, L., Lomax, M., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101340
Sharma, J., Jain, M., & Rathore, J. S. (2026) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_62_25
Chan, S. Y. C., Yau, H. C., Chan, K. Y., & Fu, A. (2026) · Cureus · doi:10.7759/cureus.114010
“Novel therapies such as apolipoprotein C-III-directed agents have transformed adult treatment but are not licensed in children [5].”
Šantić, R., Kumrić, M., Martinovic, L., Pavlović, N., Rizikalo, A., Vilović, M., Vrdoljak, J., & Božić, J. (2026) · Life · doi:10.3390/life16081298
“Phase 3 olezarsen trials demonstrate robust lowering of triglyceride-rich lipoprotein burden in defined hypertriglyceridaemic populations [34,35].”
Paquette, M., Guay, S., & Baass, A. W. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.002
ApoC-III Antisense Oligonucleotide Therapy Used in Glycogen Storage Disease Type 1a
Burns, J., Sutton, V. R., & Zachariah, J. P. V. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.109561
Park, D.-D., Bühler, A., Schöllhorn, C., & Just, S. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2716800
PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines
Kim, J., Kim, S., Yoon, M., Baek, S. J., & Shin, C. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103066 · Cited by 1
Coan, A. C. C., Katsuyama, E. S., Lopes, R. A., Sanchez, C. V., Prata, A. A., Fukunaga, C. K., Talavera, A., & Shapiro, M. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105022
Tsimikas, S., Morgan, E. S., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.012
Self-citationSabouret, P. F., Mafrica, D., Giamundo, D. M., Popiołek-Kalisz, J., Asher, E., Atar, D., & Andò, G. (2026) · Life · doi:10.3390/life16091470
Clinical significance and management of hypertriglyceridemia
Popović, L., Lukač, S. S., Rasulić, I., Petakov, A., Mitrović, M., Bogdanović, J. M., Gostiljac, D., & Lalic, K. S. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-68923
“…effect of triglyceride-level reduction on cardiovascular risk (27) and the benefit of novel therapies for acute hypertriglyceridemic pancreatitis (28), but further studies are needed to clarify how these new therapeutic options affect residual cardiovascular risk and to inform future therapeutic…”
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Where we have come from and where we are going in lipid therapeutics
Goldberg, A. C., & Duell, P. B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.001
To test or not to test: Indications and actionability in lipid genetics
Hegele, R. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.023
Self-citationChooklin, S., & Chuklin, S. S. (2026) · Gastroenterology report · doi:10.1093/gastro/goag107
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
Olezarsen for the Treatment of Hypertriglyceridemia
Rodriguez, A. S. H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_6
Development and Clinical Applications of Antisense Oligonucleotide Gapmers
Chan, L., Shaikh, F. A., Shah, P., Moriyama, H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_2
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
Tsimikas, S., Yang, X., Waldman, E., Lyu, F., Alexander, V. J., & Marcovina, S. M. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101164
Self-citationWidjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Metadata
- Authors
- Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., Witztum, J. L., & Tsimikas, S.
- Affiliations
- Western University (CA)
- From the Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, (E.S.G.S.); Ionis Pharmaceuticals, Carlsbad (V.J.A., E.K.-P., T.A.P., S.X., S.T.), and the Divisions of Endocrinology and Metabolism (J.L.W.) and Cardiovascular Medicine (S.T.), Department of Medicine, University of California, San Diego, La Jolla — both in California; the Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (R.A.H.); the Department of Translational and Precision Medicine, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome (M.A.); Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); the National Institute for Health Research and Wellcome Trust Clinical Research Facility, Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom (H.S.); and the Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (H.N.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-16
- Volume
- 390
- Issue
- 19
- Pages
- 1781-1792
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394062061
- Cited by
- 271
- References
- 37
- Citations by year
- 2026: 115 · 2025: 112 · 2024: 44
- FWCI
- 81.10
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- olezarsen, familial chylomicronemia syndrome, acute pancreatitis, hypertriglyceridemia, apolipoprotein C-III, antisense therapy, triglyceride lowering, hepatic triglyceride synthesis, dose comparison, drug safety and efficacy, adverse events, serious adverse events
- MeSH terms
- Acute Disease, Adult, Aged, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Pancreatitis, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


